Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BT revenues unexpectedly fall on weak international, handset sales

(Sharecast News) - BT Group has posted an unexpected fall in annual revenues due to lower international sales and handsets, and pointed to further declines over the coming year. The telecoms giant, which in January guided to 1-2% revenue growth from the previous year's print of £20.8bn, said revenues totalled £20.4bn in the 12 months to 31 March.

The 2% drop was due to continued challenging trading conditions in BT's Global and non-UK Portfolio channels as well as weaker handset trading in the Consumer division. This offset full fibre broadbrand growth in the Openreach unit and price increases.

Adjusted EBITDA was 1% higher than last year at £8.2bn, in line with company guidance. Reported pre-tax profit increased 12% to £1.3bn, mainly due to a goodwill impairment in the previous year.

Normalised free cash flow (NFCF) rose to £1.60bn, up from £1.28bn previously and ahead of the £1.5bn guidance.

"Although revenue declined year-on-year driven mainly by lower international sales and handsets, strong cost control and a step-up in focus and transformation resulted in growth in both EBITDA and normalised free cash flow, allowing us to increase our dividend for FY25 by 2% to 8.16p per share," said chief executive Allison Kirkby.

For the year ending March 2026, BT expects adjusted group revenues to be around £20bn, with EBITDA of £8.2bn-8.3bn and NFCF of £1.5bn.

However, the company held on to its mid-term guidance for sustained adjusted group revenue growth and EBITDA growth ahead of revenue, with NFCF rising to £2.0bn by FY27 and £3.0bn by the end of the decade.

"The momentum in, and impact of, our full fibre programme is such that we are now raising our build target by 20% to up to 5m UK premises in FY26, keeping us comfortably on track to reach 25m by the end of 2026, while maintaining our cash flow guidance. We are now only one year away from our inflection to £2bn of normalised free cash flow, our target for FY27, and remain on track to deliver £3bn by the end of the decade," Kirkby said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.